October 31, 2013
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has continued to track the supply of macroaggregated albumin (MAA). We are pleased to report that the shortages that occurred as a result of manufacturing improvements to automate the production process have been resolved. On October 11, 2013, Jubilant DraxImage Inc. (JDI), the sole supplier of MAA, reported to the U.S. Food and Drug Administration (FDA) that multiple MAA shipments were occurring. This prompted the FDA to remove MAA from its drug shortages list on October 17, 2013.
JDI’s new automated production process has proved successful. The company has been able to increase production to fully replenish MAA inventory. As a point of reference, JDI began fulfilling customers’ backorders on October 5, 2013. This was followed by another batch on October 10, 2013. Additional shipments also occurred the week of October 21, 2013, and more are to follow.
SNMMI will remain in contact with JDI. Should the situation change we will inform the nuclear medicine and molecular imaging community and other stakeholders. If you have any questions or concerns, contact your radiopharmaceutical supplier or JDI. JDI’s customer service can be reached at 1-888-633-5343 or (514) 630-7080.